Efalizumab: inflammatory neuropathies: higher than expected.
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D005060:Europe; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D009422:Nervous System Diseases / Q000139:chemically induced*
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents